Drugs / Ginseng
Ginseng
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02386852 | Mar → Nov 2014 | — | Sunway University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00029692 | Mar 2002 → Mar 2005 | — | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT00781534 Comparator | Sep 2003 → Dec 2004 | diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01712373 Comparator | Dec 2010 → Apr 2011 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ginseng | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00029692 ↗ |
| Known as | Ginsana | “1) ginseng extract (Ginsana), 2) ginkgo extract (Egb761), 3) both herbs, or 4) matching placebos.” NCT00029692 ↗ |
| Known as | ginseng extract | “1) ginseng extract (Ginsana), 2) ginkgo extract (Egb761), 3) both herbs, or 4) matching placebos.” NCT00029692 ↗ |
| Known as | Panax Ginseng | “The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo...” NCT02386852 ↗ |
| Route | Oral | “CONCLUSIONS: Oral ginseng or ginsenoside Re therapy does not improve β-cell function or IS in overweight/obese subjects with impaired glucose tolerance or newly diagnosed diabetes.” PMID 21411505 ↗ Mar 2011 |